As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
We are living in a time of extraordinary cognitive convenience and that isn’t always a good thing. AI isn’t the real risk to leadership — shallow thinking is.
We turned a two-month timeline into a sold-out 200-person event — proving that live events can elevate your brand in any industry. Learn exactly how we did it and how you can apply it to your niche.
Glen Anderson, president of Rainmaker Securities, says the secondary market for private shares has never been more active — with Anthropic the hottest trade around, OpenAI losing ground, and SpaceX’s looming IPO poised to reshape the landscape for everyone.